Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Desmopressin Nasal Spray Solution USP, 10 mcg/0.1 mL per Spray, 5 mL bottle. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Desmopressin Nasal Spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria (excessive urination) and polydipsia (drinking excessive amounts of fluids) following head trauma or surgery in the pituitary region and nocturia (excessive urination at night).
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
